Seminars in Radiation Oncology
Volume 13, Issue 1 , Pages 42-52 , January 2003

Combining bioreductive drugs and radiation for the treatment of solid tumors

References 

  1. Workman P, Stratford IJ. The experimental development of bioreductive drugs and their role in cancer therapy. Cancer Met Rev. 1993;12:73–82
  2. Brown MJ, Siim BG. Hypoxia-specific cytotoxins in cancer therapy. Semin Radiat Oncol. 1996;6:22–36
  3. Denny WA, Wilson WR, Hay MP. Recent developments in the design of bioreductive drugs. Br J Cancer. 1996;74:S32–S38
  4. Stratford IJ, Workman P. Bioreductive drugs into the next millennium. Anti-Cancer Drug Design. 1998;13:519–528
  5. Rauth AM, Melo T, Misra V. Bioreductive therapies: An overview of drugs and their mechanisms of action. Int J Radiat Oncol Biol Phys. 1998;42:755–762
  6. Wardman P. Electron transfer and oxidative stress as key factors in the design of drugs selectively active in hypoxia. Curr Med Chem. 2001;8:739–761
  7. Wouters BG, Weppler SA, Koritzinsky M, et al.  Hypoxia as a target for combined modality treatments. Eur J Cancer. 2002;38:240–257
  8. Sutherland RM. Selective chemotherapy of non-cycling cells in an in vitro tumour model. Cancer Res. 1974;34:3501–3503
  9. Kennedy KA, Teicher BA, Rockwell S, et al.  The hypoxic tumor cell: A target for selective cancer chemotherapy. Biochem Pharmacol. 1980;29:1–8
  10. Sartorelli AC. Therapeutic attack of hypoxic cells of solid tumours: presidential address. Cancer Res. 1988;48:775–778
  11. Mohindra JK, Rauth AM. Increased cell killing by metronidazole and nitrofurazone of hypoxic compared to aerobic mammalian cells. Cancer Res. 1976;36:930–936
  12. Wardman P. The chemistry of nitroarene and aromatic N-oxide radicals. In:  Alfassi ZB editors. The chemistry of N-centred radicals. New York: John Wiley; 1998;p. 98–126
  13. Stratford IJ. Split dose cytotoxic experiments with misonidazole. Br J Cancer. 1978;38:130–136
  14. Taylor YC, Rauth AM. Sulphydryls, ascorbate and oxygen as modifiers of the toxicity and metabolism of misonidazole in vitro. Br J Cancer. 1980;41:892–900
  15. Koch CJ. Unusual oxygen concentration dependence of toxicity of SR-4233, a hypoxic cell toxin. Cancer Res. 1993;53:3992–3997
  16. von Pawel J, von Roemeling R, Gatzemeier U, et al.  Tirapazamine plus cisplatin versus cisplatin in advanced non-small-cell lung cancer: A report of the international CATAPULT I study group. Cisplatin and Tirapazamine in Subjects with Advanced Previously Untreated Non-Small-Cell Lung Tumors. J Clin Oncol. 2000;18:1351–1359
  17. Walton MI, Workman P. Nitroimidazole bioreductive metabolism: Quantitation and characterisation of mouse tissue benzonidazole nitroreductases in vivo and in vitro. Biochem Pharmacol. 1987;36:887–896
  18. Patterson AV, Saunders MP, Chinje EC, et al.  Overexpression of human NADPH: Cytochrome c (P450) reductase confers enhanced sensitivity to both tirapazamine (SR 4233) and RSU 1069. Br J Cancer. 1997;76:1338–1347
  19. Walton MI, Workman P. Enzymology of the reductive bioactivation of SR 4233: A novel benzotriazine di-N-oxide hypoxic cell cytotoxin. Biochem Pharmacol. 1990;39:1735–1742
  20. Patterson AV, Barham HM, Chinje EC, et al.  Importance of P450 reductase activity in determining sensitivity of breast tumour cells to the bioreductive drug, tirapazamine (SR 4233). Br J Cancer. 1995;72:1144–1150
  21. Saunders MP, Jaffar M, Patterson AV, et al.  The importance of P450 reductase for determining the sensitivity of human tumour cells to the indolequinone E09 and related analogues lacking functionality in the C-2 and C-3 positions. Biochem Pharmacol. 2000;59:993–996
  22. Bridgewater JA, Springer CJ, Knox RJ, et al.  Expression of the bacterial nitroreductases enzyme in mammalian cells renders them selectively sensitive to killing by the prodrug CB1954. Eur J Cancer. 1995;31:2362–2370
  23. Airley R, Loncaster J, Davidson S, et al.  Glucose transporter Glut-1 expression correlates with tumour hypoxia and predicts metastasis free survival in advanced carcinoma of the cervix. Clin Cancer Res. 2001;7:928–934
  24. Loncaster JA, Harris AL, Davison SE, et al.  CA IX expression, a potential new intrinisic marker of hypoxia: correlations with tumor oxygen measurements and prognosis in locally advanced carcinoma of the cervix. Cancer Res. 2001;61:6394–6399
  25. Brown JM, Yu NY, Cory MJ, et al.  In vivo evaluation of the radio-sensitizing and cytotoxic properties of newly synthesized electron-affinic drugs. Br J Cancer. 1978;37(suppl):206–211
  26. Stewart F. The effects of hyperthermia and ionizing radiation on bladder, skin and an experimental tumour in mice [doctoral thesis]. London: University of London; 1978;
  27. Taylor YC, Rauth AM. Differences in the toxicity and metabolism of the 2-nitroimidazole misonidazole (Ro-07-0582) in HeLa and CHO cells. Cancer Res. 1978;38:2745–2752
  28. Rockwell S. Effects of some proliferative and environmental factors on the toxicity of mitomycin C to tumor cells in vitro. Int J Cancer. 1986;38:229–235
  29. Stratford IJ, O'Neill P, Sheldon PW, et al.  RSU 1069, a nitroimidazole containing an aziridine group: Bioreduction greatly increases cytotoxicity under hypoxic conditions. Biochem Pharmacol. 1986;35:105–110
  30. O'Neill P, McNeil SS, Jenkins TC. Induction of DNA crosslinks in vitro upon reduction of the nitroimidazole-aziridines RSU-1069 and RSU-1131. Biochem Pharmacol. 1987;36:1787–1792
  31. Stratford IJ, Adams GE, Godden J, et al.  Induction of tumour hypoxia post-irradiation: A method for increasing the sensitizing efficiency of misonidazole and RSU 1069 in vivo. Int J Radiat Biol. 1989;55:411–422
  32. Stratford J. Bioreductive drugs in cancer therapy. Br J Radiol. 1992;24(suppl):128–136
  33. Horwich A, Holliday SB, Deacon JM, et al.  A toxicity and pharmacokinetics study in man of the hypoxic radiosensitizer RSU-1069. Br J Radiol. 1986;59:1238–1240
  34. Bremner JC. Assessing the bioreductive effectiveness of the nitroimidazole RSU1069 and its prodrug RB6145: With particular reference to in vivo methods of evaluation. Cancer Met Rev. 1993;12:177–193
  35. Jenkins T, Naylor MA, O'Neill P, et al.  Synthesis and evaluation of alpha-[)2-haloethyl)amino]methyl]-2-nitro-1H-imidazole-1-ethanols as prodrugs of alpha-[(1-aziridinyl)methyl-2- nitro-1H-imidazole-1-ethanol (RSU-1069) and its analogues which are radiosensitizers and bioreductively activated cytotoxins. J Med Chem. 1990;33:2603–2610
  36. Binger M, Workman P. Pharmacokinetic contribution to the improved therapeutic selectivity of a novel bromoethylamino prodrug (RB 6145) of the mixed-function hypoxic cell sensitizer/cytotoxin alpha-(1-aziridinomethyl)-2-nitro-1H-imidazole-1-ethanol (RSU 1069). Cancer Chem Pharmacol. 1991;29:37–47
  37. Lee AE, Wilson WR. Hypoxia-dependent retinal toxicity of bioreductive anticancer prodrugs in mice. Toxicol Appl Pharmacol. 2000;163:50–59
  38. Zeman EM, Brown JM, Lemmon MJ, et al.  SR-4233: A new bioreactive agent with high selective toxicity for hypoxic mammalian cells. Int J Radiat Oncol Biol Phys. 1968;12:1239–1242
  39. Zeman EM, Hirst VK, Lemmon MJ, et al.  Enhancement of radiation-induced tumor cell killing by the hypoxic cell toxin SR 4233. Radiother Oncol. 1988;12:209–218
  40. Zeman EM, Brown JM. Pre-and post-irradiation radiosensitization by SR 4233. Int J Rad Oncol Biol Phys. 1989;16:967–971
  41. Biedermann KA, Wang J, Graham RP, et al.  SR4233 cytotoxicity and metabolism in DNA repair-competent and repair-deficient cell cultures. Br J Cancer. 1991;63:358–362
  42. Wang J, Biedermann KA, Brown JM. Repair of DNA and chromosome breaks in cells exposed to SR4233 under hypoxia and to ionising radiation. Cancer Res. 1992;52:4473–4477
  43. Stratford IJ, Stephens MA. The differential hypoxic cytotoxicity of bioreductive agents determined in vitro by the MTT assay. Int J Radiat Oncol Biol Phys. 1989;16:973–976
  44. Brown JM, Lemmon MJ. Potentiation by the hypoxic cytotoxin SR4233 of cell killing produced by fractionated irradiation of mouse tumours. Cancer Res. 1990;50:7745–7749
  45. Dorie MJ, Menke D, Brown JM. Comparison of the enhancement of tumor responses to fractionated irradiation by SR 4233 (tirapazamine) and by nicotinamide with carbogen. Int J Radiat Oncol Biol Phys. 1994;28:145–150
  46. Brown JM, Giaccia AJ. Tumour hypoxia: The picture has changed in the 1990s. Int J Radiat Biol. 1994;65:95–102
  47. Hill RP. Sensitizers and radiation dose fractionation: Results and interpretations. Int J Radiat Oncol Biol Phys. 1986;12:1049–1054
  48. Brown JM, Lemmon MJ. Fractionation increases the antitumour effect of adding a hypoxic cytotoxin to irradiation. In:  Dewey WC editors. Radiation research a twentieth century perspective. San Diego, CA: Academic; 1992;p. 807–812
  49. Rockwell S, Sartorelli AC. Mitomycin C and radiation. In:  Hill BT editors. Antitumor drug-radiation interactions. Boca Raton, FL: CRC Press, Inc; 1990;p. 126–139
  50. Weissberg JB, Papac RJ, Son YH, et al.  Randomized clinical trial of mitomycin C as an adjunct to radiotherapy in head and neck cancer. Int J Radiat Oncol Biol Phys. 1989;17:3–9
  51. Haffty BG, Son YH, Sasaki CT, et al.  Mitomycin C as an adjunct to postoperative radiation therapy in squamous cell carcinoma of the head and neck: results from two randomized clinical trials. Int J Radiat Oncol Biol Phys. 1994;27:241–250
  52. Rockwell S, Keyes SR, Sartorelli AC. Preclinical studies of porfiromycin as an adjunct to radiotherapy. Radiat Res. 1988;116:100–113
  53. Belcourt MF, Hodnick WF, Rockwell S, et al.  Exploring the mechanistic aspects of mitomycing antibiotic bioactivation in Chinese hamster ovary cells overexpressing NADPH: Cytochrome C (P450) reductase and DT-diaphorase. Adv Enzyme Regul. 1998;38:111–133
  54. Powis G. Metabolism and reactions of quinoid anticancer agents. Pharmacol Ther. 1987;35:57–162
  55. Keyes SR, Fracasso PM, Heimbrook DC, et al.  Role of NADPH: Cytochrome c reductase and DT-diaphorase in the biotransformation of mitomycin C. Cancer Research. 1984;44:5638–5643
  56. Haffty BG, Son YH, Wilson LD, et al.  Bioreductive alkylating agent porfiromycin in combination with radiation therapy for the management of squamous cell carcinoma of the head and neck. Radiat Oncol Investig. 1997;5:235–245
  57. Robertson N, Haigh A, Adams GE, et al.  Factors affecting sensitivity to EO9 in rodent and human tumour cells in vitro: DT-diaphorase activity and hypoxia. Eur J Cancer. 1994;30A:1013–1019
  58. Plumb JA, Workman P. Unusually marked hypoxic sensitisation to indoloquinone EO9 and mitomycin C in a human colon-tumour cell line that lacks DT-diaphorase activity. Int J Cancer. 1994;56:134–139
  59. Adams GE, Stratford IJ. Bioreductive drugs for cancer therapy: The search for tumor specificity. Int J Radiat Oncol Biol Phys. 1994;29:231–238
  60. Jaffar M, Naylor MA, Robertson N, et al.  5-Substituted analogues of 3-hydroxymethyl-5-arziridinyl-1-methyl-2-[1H-indole-4, 7-dione]prop-2-en-ol (E09, NSC 382459) and their regiosomers as hypoxia-selective agents: Structure-cytotoxicity in vitro. Anticancer Drug Des. 1998;13:105–123
  61. Smitskamp-Wilms E, Hendriks HR, Peters GJ. Development, pharmacology, role of DT-diaphorase and prospects of the indolequinone EO9. Gene Pharmacol. 1996;27:421–429
  62. Schellens JH, Planting AS, van Acker BA, et al.  Phase I and pharmacologic study of the novel indoloquinone bioreductive alkylating cytotoxic drug EO9. J Nat Cancer Inst. 1994;86:906–912
  63. Pavlidis N, Hanauske AR, Gamucci T, et al.  A randomized phase II study with two schedules of the novel indoloquinone EO9 in non-small-cell lung cancer: A study of the EORTC early clinical studies group (ECSG). Ann Oncol. 1996;7:529–531
  64. Patterson LH. Rationale for the use of aliphatic N-oxides of cytotoxic anthraquinones as prodrug DNA binding: A new class of bioreductive agent. Cancer Met Rev. 1993;12:119–134
  65. McKeown SR, Hejmadi MV, McIntyre IA, et al.  AQ4N: An alkylaminoanthraquinone N-oxide showing bioreductive potential and positive interaction with radiation in vivo. Br J Cancer. 1995;72:76–81
  66. McKeown SR, Friery OP, McIntyre IA, et al.  Evidence for a therapeutic gain when AQ4N or tirapazamine is combined with radiation. Br J Cancer. 1996;27(suppl):S39–S42
  67. Patterson LH, McKeown SR, Robson T, et al.  Antitumour prodrug development using cytochrome P450 (CYP) mediated activation. Anticancer Drug Des Dec. 1999;14:473–486
  68. Everett SA, Naylor MA, Patel KB, et al.  Bioreductively-activated prodrugs for targeting hypoxic tissues: Elimination of Aspirin from 2-nitroimidazole derivatives. Bio Med Chem Lett. 1999;9:1267–1272
  69. McNally VA, Patterson AV, Williams KJ, et al.  Antiangiogenic, bioreductive and gene therapy approaches to the treatment of hypoxic tumours. Curr Pharm Des. 2002;1319–1333
  70. Wardman P, Derris MF, Everett SA. Radicals from one-electron reduction of nitro compounds, aromatic-N-oxides and quinones: The kinetic basis for hypoxia-selective bioreductive drugs. Biochem Soc Symp. 1995;61:171–178
  71. Marshall RS, Rauth AM. Modification of the cytotoxic activity of mitomycin C by oxygen and ascorbic acid in chinese hamster ovary cells and in a repair deficient mutant. Cancer Res. 1986;46:2709–2713
  72. Mulcahy RT. Effect of oxygen on misonidazole chemosensitization and cytotoxicity in vitro. Cancer Res. 1984;44:4409–4413
  73. Hall EJ. Radiobiology for the radiologist. In: New York: Lippincott,; 1988;p. 143
  74. Brown JM. SR 4233 (Tirapazamine): A new anticancer drug exploiting hypoxia in solid tumours. Br J Cancer. 1993;67:1163–1170
  75. Butler J, Sparswick VJ, Cummings J. The autooxidation of the reduced forms of E09. Free Radical Res. 1996;25:141–148
  76. Shibata T, Giaccia AJ, Brown JM. Hypoxia-inducible regulation of a prodrug-activating enzyme for tumor-specific gene therapy. Neoplasia. 2002;4:40–48
  77. Patterson AV, Williams KJ, Cowen RL, et al.  Oxygen-sensitive gene-directed enzyme-prodrug therapy (O2-GDEPT) for solid tumours: Potentially curative when combined with x-rays. Gene Ther. 2002;9:946–954
  78. Overgaard J, Hansen HS, Overgaard M, et al.  A randomized double-blind phase III study of nimorazole as a hypoxic radiosensitizer of primary radiotherapy in supraglottic larynx and pharynx carcinoma. Results of the Danish Head and Neck Cancer Study (DAHANCA) Protocol 5-85. Radiother Oncol. 1998;46:135–146
  79. Damen EW, Nevalainen TJ, van den Bergh TJ, et al.  Synthesis of novel paclitaxel prodrugs designed for bioreductive activation in hypoxic tumour tissue. Bioorg Med Chem. 2002;10(1):71–77
  80. Papadopoulou MV, Ji M, Rao MK, et al.  4-[3-(2-Nitro-1-imidazolyl)propylamino]-7-chloroquinoline hydrochloride (NLCQ-1), a novel bioreductive agent as radiosensitizer in vitro and in vivo: Comparison with tirapazamine. Oncol Res. 2000;12:325–333
  81. Tercel M, Lee AE, Hogg A, et al.  Hypoxia-selective antitumor agents. 16. Nitroarylmethyl quaternary salts as bioreductive prodrugs of the alkylating agent mechlorethamine. J Med Chem. 2001;11:3511–3522
  82. Gali-Muhtasib HU, Haddadin MJ, Rahhal DN, et al.  Quinoxaline 1,4-dioxides as anticancer and hypoxia-selective drugs. Oncol Rep. 2001;8:679–684
  83. Sun ZY, Botros E, Su AD, et al.  Sulfoxide-containing aromatic nitrogen mustards as hypoxia-directed bioreductive cytotoxins. J Med Chem. 2000;43:4160–4168

☆ Supported by the Medical Research Council Grant Number G9520193.

☆☆ Address reprint requests to Ian J. Stratford, PhD, School of Pharmacy and Pharmaceutical Sciences, University of Manchester Coupland III Building, Oxford Road, Manchester M13 9PL, UK.

PII: S1053-4296(03)50007-8

doi: 10.1053/srao.2003.50008

Seminars in Radiation Oncology
Volume 13, Issue 1 , Pages 42-52 , January 2003

Article Tools

* Image Usage & Resolution